Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | An overview of optimal sequencing therapy in AML

Prapti Patel • 14 Dec 2021
ASH 2021
Acute Myeloid Leukemia Leukemia Azacitidine Venetoclax
VIALE-A VIALE-C

Prapti Patel, MD, University of Texas Southwestern Medical Center, Dallas, TX, gives an overview on therapy sequencing in acute myeloid leukemia (AML), and mentions the importance of the clinical data that is currently available, such as from the VIALE-A and VIALE-C trials (NCT02993523, NCT03069352). Dr Patel then mentions the importance of focusing on the biology of disease to better understand how to develop novel therapies in the future. This interview took place at the 63rd ASH Annual Meeting and Exposition Congress, Atlanta, GA, 2021.

Disclosures

BMS-Celgene, Agios: Membership on an entity’s Board of Directors or advisory committees; Peerview: Honoraria.

More from Prapti Patel

4:11
Venetoclax based combination therapy in AML: a real-world retrospective analysis
Prapti Patel • 14 Dec 2021
4:51
Updates from the Beat AML Master Trial
Prapti Patel • 14 Dec 2021
1:48
Treatment options for patients with AML that are not candidates for intensive chemotherapy
Prapti Patel • 14 Dec 2021

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals